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A healthcare worker (HCW) receiving anti-TNF therapy presented with a second episode of 
tuberculosis. The Mycobacterium tuberculosis isolated differed from the first episode by whole-
genome sequencing, but matched a patient’s isolate which, despite them having had minimal 
contact, proved nosocomial transmission. Careful occupational risk assessment of HCWs receiving 
immunosuppressants is advised.  
 
A 37-year-old female, HIV negative HCW with a history of ankylosing spondylitis requiring the anti-
TNF agent Etanercept presented with an abrupt onset of wheeze and fever. Examination and a chest 
radiograph suggested right upper lobe consolidation prompting antibiotic treatment for community 
acquired pneumonia. Seven months prior to this she recalled a self-resolving, several week history of 
dry cough. Eight years previously, after returning from voluntary healthcare work in Africa, she had 
drug sensitive tuberculosis (TB), for which she received 6 months standard treatment. She was left 
with residual mild lower lobe bronchiectasis.  
 
On this presentation, a sputum sample was negative for acid-fast bacilli on smear microscopy but an 
Xpert MTB/RIF (Cepheid, CA, USA) molecular test was positive for Mycobacterium tuberculosis 
(M.tb), and negative for genetic mutations associated with rifampicin resistance. Antibiotics were 
stopped and the patient was commenced on standard anti-TB treatment of rifampicin, isoniazid, 
ethambutol and pyrazinamide. Drug sensitive M.tb was isolated after 14 days growth in liquid MGIT 
culture (Bactec MGIT™ 960, Becton Dickinson (BD) Microbiology Systems, Sparks, MD, USA).  
 
As part of the epidemiological investigation, MIRU-VNTR (Mycobacterial Interspersed Repeat Unit-
Variable Number Tandem Repeat) genotyping was performed which identified an isolate that 
differed in 9 loci when compared to her previous isolate, thereby excluding reactivation of her 
previous TB (figure 1a). However, it did match a previously unique isolate in the National 
Mycobacterial Reference Laboratory (NMRL) database which had been identified in a person living 
with HIV (PLWH) diagnosed 2 years previously with smear positive drug sensitive pulmonary TB. 
Whole genome sequencing (WGS), using Illumina HiSeq platform (Illumina, San Diego, USA), 
confirmed the findings of the routine typing with 1 single nucleotide polymorphism (SNP) difference 
between the PLWH and HCW isolate, and refuted any link with the HCW’s previous M.tb isolate 
which differed by 422 SNPs (figure 1b; generated using PopART Population Analysis with Reticulate 
Trees, New Zealand).   
 
At the time of his diagnosis, the PLWH had been admitted to hospital and placed in a bay on the 
general Infectious Diseases ward. On the day of admission, a sputum sample was smear-microscopy 
positive for acid fast bacilli (smear grade 1+) and respiratory infection control practices were 
instituted immediately, including respiratory precautions with FFP3 masks for prolonged patient 
contact and aerosol-generating procedures in a negative pressure isolation room. Extensive 
investigation was undertaken to assess exposure to staff, patients and contacts and adherence to 
infection control procedures.  
 
During this patient’s admission, the HCW had worked in the hospital and on the Infectious Diseases 
ward in a largely managerial role. The HCW was not involved in routine day-to-day patient care.  
There was no reported face-to-face contact with the index patient prior to, or after, patient 
isolation.  Reviewing shift patterns and work diaries, the overlap between the two cases on the same 
ward was minimal and estimated to be less than 30 minutes. No other HCW developed active TB and 
there were no Tuberculin Skin Testing (TST)/Interferon Gamma-Release Assay (IGRA) conversions to 
suggest transmission to other HCW or social contacts.  
 
Nosocomial transmission of TB has been well-documented in seminal experiments conducted by 
Riley et al in the 1950s, where guinea pigs in air ventilation ducts from a TB ward were frequently 
infected (1). HCWs are often affected, with epidemiological surveys routinely identify HCWs as being 
at higher risk of TB, even in low incidence settings (2, 3). Infection control measures to reduce 
occupational TB transmission in the UK, including the use of isolation rooms, negative pressure 
ventilation and FFP3 masks for aerosol-generating procedures,  are only partially effective,  and 
healthcare workers remain at increased risk (4). The WHO (World Health Organisation) recommends 
four levels of infection control measures to effectively control TB, including managerial, 
administrative, and environmental controls and personal respiratory protection, but these are often 
poorly implemented in resource-limited settings (5).  
 
There are scant data on the occupational risk of TB in HCW receiving anti-TNF therapy, although 
these drugs increase the relative risk of TB up to 25-fold in the general population (6). They are often 
used as disease modifiers in rheumatological and other inflammatory disorders, and so are 
frequently introduced early in the clinical pathway.  The Joint Tuberculosis Committee of the British 
Thoracic Society provided guidance  to reduce the risk of TB in patients commencing anti-TNF 
therapies (7). They recommended that active TB should be excluded, or treated for at least 2 months 
prior to commencing anti-TNF treatment. Patients with latent TB should be offered 
chemoprophylaxis where the risk of TB exceeded that of drug-induced hepatitis. This favours 
treating HCW at any age, given their higher risk of active TB.  They proposed that patients such as 
this HCW, with a history of previous adequately treated TB, should be monitored clinically every 3 
months during anti-TNF therapy; those with respiratory symptoms should have with a chest 
radiograph and sputum examination for TB performed.      
 
Given the increased risk of TB during anti-TNF therapy, occupational restrictions on HCWs are 
sensible, though there is little evidence on which to base what may be career-limiting decisions. 
Prior to the advent of molecular typing, occupational transmission events were frequently 
misclassified using routine epidemiological investigations. One study of presumed occupationally 
acquired TB in Denmark, a low TB burden country,  indicated that one third of these cases were in 
fact ‘unlikely’ on the basis of Restriction Fragment Length Polymorphism (RFLP) and/or MIRU typing 
(8).  WGS offers unrivalled resolution to confirm or refute transmission events, with greater 
discrimination than MIRU-VNTR, and identify missing links in chains of transmission, even where 
people in the chain remain unknown (9). WGS may also be able to demonstrate “directionality” of 
transmission given the biological rarity of backward mutations (10). The technology is limited by the 
current lack of national and international databases of strains – such that in this case we are unable 
to investigate whether the unique isolate from the PLWH was part of a larger international genetic 
grouping.  
  
The minimal contact between the patient and HCW that led to transmission, despite standards of 
infection control expected in a specialist Infectious Diseases unit in a high income country, highlights 
the challenge in protecting HCW with immuno-compromise and is a concern. In resource limited 
settings, the occupational risk of TB to HCWs is greater and TB infection control measures more 
challenging (5). This is compounded in areas where the prevalence of HIV co-infection is higher. A 
case-control study of HCWs in  South Africa, a country with a very high prevalence of HIV in the 
general population at 17%, identified HIV as conferring a greater than 6-fold risk of occupational TB 
compared to non-HIV infected HCWs (11).  The additional challenges of poor outcomes in HCWs 
managing drug resistant TB, plus the impact on the health and financial well-being of their families, 
raise further ethical issues surrounding the sociopolitical aspects of infection control and highlight 
the responsibility of the state to protect and support those HCW who place themselves at risk in the 
line-of-duty. Moreover, the extension of TB care to community and home-based settings is likely to 
further complicate infection control procedures, and should be considered in future efforts to 
protect HCW (12). 
 
This case highlights the risk of occupational TB transmission in a HCW receiving anti-TNF therapy 
after minimal exposure, despite adherence to reasonable infection control precautions in a resource 
rich setting. Further data are required to quantify the occupational risk of TB in HCWs receiving anti-
TNF therapies and so provide the evidence for sensible and safe infection control policies.  
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 Figure 1 
 
a. MIRU-VNTR typing healthcare worker (HCW) and patient living with HIV (PLWH) 
Mycobacterium tuberculosis isolates compared to HCW previous historical isolate; 
differences highlighted in grey 
 
Isolate MIRU-VNTR typing  
PLWH 2 1 4 3 3 2 4 2 2 6 1 6 3 2 1 4 3 4 4 1 5 2 - 2 
HCW 2 1 4 3 3 2 4 2 2 6 1 6 3 2 1 4 3 4 4 1 5 2 7 2 
  
HCW 
(2006) 
2 2 2 3 5 2 4 2 2 6 - 4 3 2 3 4 3 4 4 2 1 1 3 2 
 
  
b. Representation of Mycobacterium tuberculosis isolates identified by whole genome 
sequencing; purple circles represent patient and HCW TB isolates, numbers in brackets show 
single nucleotides variations (SNPs) between isolates , supporting transmission between 
PLWH and HCW with isolates (1 SNP)  and distinct from HCW workers previous episode (422 
SNPs) 
 
 
PLWH 
HCW 
(current) 
HCW 
2006 
